|
⚲
|
| Message |
|---|
| Happy Holidays!! thanks for using AUM13F!! |
| Caligan Partners LP
✚
|
|
|---|---|
| CRD # | 289887 |
| SEC # | 801-113810 |
| CIK # | 0001727492 |
| AUM | $419.0 M (2025-07-10) |
| Employees | 5 (100% Investors, 0% Brokers) |
| Phone | 646-859-8204 |
| Address | 780 Third Avenue New York, NY 10017 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| CIK | Period |
|---|---|
| 0001727492 |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Verona Pharma PLC | 135.9 | ||
| Liquidia Corp | 101.2 | ||
| Exelixis Inc | 67.2 | ||
| Agios Pharmaceuticals Inc | 35.6 | ||
| Merus NV | 34.6 | ||
| Evolus Inc | 30.8 | ||
| Mineralys Therapeutics Inc | 27.3 | ||
| Revolution Medicines Inc | 23.4 | ||
| Anika Therapeutics Inc | 15.2 | ||
| Abivax Sa | 12.8 | ||
| Y-Mabs Therapeutics Inc | 10.6 | ||
| FITS My Style Inc | 6.9 | ||
| Biocryst Pharmaceuticals Inc | 5.7 | ||
| RXI Pharmaceuticals Corp | 5.0 | ||
| Verrica Pharmaceuticals Inc | 4.9 | ||
| TYRA Biosciences Inc | 1.8 | ||
| AURA Biosciences Inc | 1.3 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold ($M) | AUM ($M) |
|---|---|---|---|---|
| HF | Caligan Partners CV VII LP | 2024-03-28 | 0.0 | |
| HF | Caligan Partners CV VI LP | [2024-03-28] | 14.6 | 36.0 |
| HF | Caligan Partners CV IV LP | [2022-03-30] | 18.2 | 60.1 |
| HF | Caligan Partners CV V LP | [2022-03-30] | 18.2 | 9.6 |
| HF | Caligan Partners Master Fund LP | [2022-03-30] | 11.5 | 223.2 |
| HF | Caligan Partners CV III LP | [2021-03-25] | 33.9 | 42.2 |
| HF | Caligan Partners CV II LP | 2020-03-26 | 39.9 | |
| HF | Caligan Partners CV I LP | [2019-02-04] | 19.0 | 23.8 |
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 419.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 7 | 419.0 |
| By Discretionary | ||
| Discretionary | 7 | 419.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 7 | 419.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 173.2 | |
| United States Persons | 245.9 | |
| Total | 7 | 419.0 |
| Form D Directors | # Filings | # Firms | 2011 - 2025 |
|---|---|---|---|
| Syed Asad Mahmood | 4 | ||
| Daphne Pit Hogenes | 3 | ||
| Caligan Partners LP | 6 | ||
| Caligan Partners CV IV LP | 1 | ||
| Caligan Partners CV III GP LLC | 1 | ||
| Caligan Partners CV VI GP LLC | 1 | ||
| Samuel Merksamer | 1 | ||
| Caligan Partners CV GP LLC | 1 | ||
| Caligan Partners CV IV GP LLC | 1 |
| EDGAR Form | CIK | 2011 - 2025 |
|---|---|---|
| 13F-HR | [0001727492] | |
| 3 | [0001727492] | |
| 4 | [0001727492] | |
| SC 13D | [0001727492] | |
| SC 13G | [0001727492] |
| Form 3/4/5 Subject | 2011 - 2025 |
|---|---|
| Liquidia Corp | |
| Caligan Partners LP | |
| Johnson David Edward | |
| Exelixis Inc | |
| Alimera Sciences Inc | |
| Standard Biotools Inc | |
| AMAG Pharmaceuticals Inc | |
| Merksamer Samuel J |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Gardner Lewis Asset Management LP
✚
|
PA | 0.4 |
|
Valueworks LLC
✚
|
NY | 0.4 |
|
Venator Management LLC
✚
|
PA | 0.4 |
|
Gables Capital Management Inc
✚
|
FL | 0.4 |
|
Lavaca Capital LLC
✚
|
TX | 0.4 |
|
Taylor Hoffman Capital Management LLC
✚
|
VA | 0.4 |
|
Obrien Greene & Co Inc
✚
|
PA | 0.4 |
|
Gold Coast Wealth Management LLC
✚
|
NY | 0.4 |
|
Charter Capital Management LLC
✚
|
WI | 0.4 |
|
SB Advisory LLC
✚
|
GA | 0.4 |